Findings

What do systematic reviews say?

55 questions · 55 findings · 9 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 10 · 18.2%GRADE not reported 0 · 0%Very low 17 · 30.9%Low 19 · 34.5%Moderate 8 · 14.5%High 1 · 1.8%

Oral 5‐aminosalicylic acid vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.56 [0.14, 2.22]
1 study · 95 participants
Low

Oral 5‐aminosalicylic acid vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.25
5 studies · 457 participants
Very low

Oral 5‐aminosalicylic acid vs placebo

Adverse events · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.93 [0.73, 1.18]
5 studies · 1132 participants
Moderate

Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Minor adverse events · people with active UC

The review found no eligible studies for this question.

1 finding from 1 review

Probiotics for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral 5‐aminosalicylic acid vs sulfasalazine

Serious adverse events · Patients with quiescent ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral 5‐aminosalicylic acid vs placebo

Serious adverse events · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.6 [0.19, 1.84]
3 studies · 826 participants
Low

Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · people with active UC

The review found no eligible studies for this question.

1 finding from 1 review

Probiotics for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Withdrawals due to adverse events · people with active UC

The review found no eligible studies for this question.

1 finding from 1 review

Probiotics for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · Patients with quiescent ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).

1 finding from 1 review

Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 5.29 [0.26, 107.63]
2 studies · 127 participants
Very low

Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Adverse events · people with surgically‐induced remission in Crohn's disease

Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with 5‐aminosalicylic acid (low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.89 [0.74, 1.07]
4 studies · 346 participants
Low

Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Minor adverse events · people with active UC

It is very uncertain whether probiotics changes minor adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).

1 finding from 1 review

Probiotics for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1
2 studies · 192 participants
Very low

Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · people with active UC

It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).

1 finding from 1 review

Probiotics for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.21 [0.01, 4.22]
1 study · 116 participants
Very low

Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with 5‐aminosalicylic acid (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 3.39 [1.26, 9.13]
3 studies · 311 participants
Very low

Oral 5‐ASA vs SASP

Adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.48 [0.36, 0.63]
12 studies · 909 participants
Moderate

Once daily dosing vs conventional dosing

Adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in adverse events compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.02 [0.89, 1.18]
4 studies · 1586 participants
Moderate

Oral 5‐ASA vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in adverse events compared with comparator 5‐ASA (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.01 [0.92, 1.12]
9 studies · 1576 participants
Moderate

Oral 5‐ASA vs placebo

Adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in adverse events compared with placebo (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.95 [0.85, 1.07]
8 studies · 1218 participants
High

5‐ASA vs placebo

Adverse events · people with surgically‐induced remission in Crohn's disease

5‐ASAs showed no clear difference in adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.07 [0.6, 1.91]
4 studies · 466 participants
Low

High dose 5‐ASA vs low dose 5‐ASA

Adverse events · people with surgically‐induced remission in Crohn's disease

High dose 5‐ASA showed no clear difference in adverse events compared with low dose 5‐ASA (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.04 [0.15, 7.24]
1 study · 206 participants
Low